{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:36:42Z","timestamp":1793860602975,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For many indications, BoNT\/A is repetitively injected with the risk of developing neutralizing antibodies (NABs). Therefore, it is important to analyze whether there is a difference in antigenicity between the different licensed BoNT\/A preparations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cross-sectional study, the prevalence of NABs was tested by means of the sensitive mouse hemidiaphragm assay (MHDA) in 645 patients. Patients were split into those having exclusively been treated with the complex protein-free incoBoNT\/A preparation (CF-MON group) and those having started BoNT\/A therapy with a complex protein-containing BoNT\/A preparation (CC-I group). This CC-I group was split into those patients who remained either on abo- or onaBoNT\/A (CC-MON group) and those who had been treated with at least two BoNT\/A preparations (CC-SWI group). To balance treatment duration, only CC-MON patients who did not start their BoNT\/A therapy more than 10\u00a0years before recruitment (CC-MON-10 group) were further analyzed. The log-rank test was used to compare the prevalence of NABs in the CF-MON and CC-MON-10 group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the CF-MON subgroup, no patient developed NABs. In the CC-I group, 84 patients were NAB-positive. NABs were found in 33.3% of those who switched preparations (CC-SWI) and in 5.9% of the CC-MON-10 group. Kaplan\u2013Meier curves for remaining NAB-negative under continuous BoNT\/A therapy were significantly different (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.035) between the CF-MON and CC-MON-10 group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Frequent injections of a complex protein-containing BoNT\/A preparation are associated with significantly higher risks of developing NABs than injections with the same frequency using the complex protein-free incoBoNT\/A preparation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11395-2","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:02:31Z","timestamp":1664935351000},"page":"788-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-7684","authenticated-orcid":false,"given":"Harald","family":"Hefter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Brauns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"\u00dcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Ih","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"11395_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","volume":"15","author":"J Frevert","year":"2015","unstructured":"Frevert J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 15:1\u20139","journal-title":"Drugs R D"},{"key":"11395_CR2","unstructured":"International Society of Aesthetic Plastic Surgeons. ISAPS international survey on aesthetic\/cosmetic procedures performed in 2013. http:\/\/www.isaps.org\/news\/isaps-global-statistics"},{"key":"11395_CR3","doi-asserted-by":"publisher","first-page":"e1982","DOI":"10.1212\/WNL.0000000000007368","volume":"92","author":"WH Jost","year":"2019","unstructured":"Jost WH, Friedman A, Michel O et al (2019) SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 92:e1982\u2013e1991","journal-title":"Neurology"},{"key":"11395_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","volume":"11","author":"S Bellows","year":"2019","unstructured":"Bellows S, Jankovic J (2019) Immunogenicity associated with botulinum toxin treatment. Toxins 11:491. https:\/\/doi.org\/10.3390\/toxins11090491","journal-title":"Toxins"},{"key":"11395_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","volume":"8","author":"KR Aoki","year":"2001","unstructured":"Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8:21\u201329","journal-title":"Eur J Neurol"},{"key":"11395_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","volume":"216","author":"MZ Atassi","year":"2011","unstructured":"Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216:782\u2013792","journal-title":"Immunobiology"},{"key":"11395_CR7","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19:S92-100","journal-title":"Mov Disord"},{"key":"11395_CR8","doi-asserted-by":"publisher","first-page":"175628641989207","DOI":"10.1177\/1756286419892078","volume":"12","author":"H Hefter","year":"2019","unstructured":"Hefter H, Rosenthal D, Bigalke H, Moll M (2019) Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Ther Adv Neurol Disord 12:1756286419892078","journal-title":"Ther Adv Neurol Disord"},{"key":"11395_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J et al (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 86:1818\u20131826","journal-title":"Neurology"},{"key":"11395_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217","journal-title":"Mov Disord"},{"key":"11395_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, Jansen A, Lee JI et al (2019) High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 92:e48-54","journal-title":"Neurology"},{"key":"11395_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J (2010) Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae. Drugs R D 10:67\u201373","journal-title":"Drugs R D"},{"key":"11395_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu S, Rumpel S, Zhou J et al (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977\u2013981","journal-title":"Science"},{"key":"11395_CR14","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"key":"11395_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"JK Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245\u2013247","journal-title":"Lancet"},{"key":"11395_CR16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186\u20131188","journal-title":"Neurology"},{"key":"11395_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"11395_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1504\/TBJ.2008.018956","volume":"1","author":"N Panjwani","year":"2008","unstructured":"Panjwani N, O\u2019Keeffe R, Pickett A (2008) Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 1:153\u2013166","journal-title":"Botulinum J"},{"key":"11395_CR19","first-page":"238","volume":"9","author":"J Bl\u00fcmel","year":"2006","unstructured":"Bl\u00fcmel J, Frevert J, Schwaier A (2006) Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotox Res 9:238","journal-title":"Neurotox Res"},{"key":"11395_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mdc3.12322","volume":"3","author":"H Hefter","year":"2016","unstructured":"Hefter H, Rosenthal D, Moll M (2016) High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Mov Disord Clin Pract 3:500\u2013506","journal-title":"Mov Disord Clin Pract"},{"key":"11395_CR21","first-page":"S38","volume":"123","author":"H Hefter","year":"2016","unstructured":"Hefter H, Jansen A, Moll M, Ringelstein M, Albrecht P (2016) High prevalence of neutralizing antibodies in BoNT\/A long-term\u2013treated patients with focal dystonia and spasticity. Toxicon 123:S38\u2013S39","journal-title":"Toxicon"},{"key":"11395_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fneur.2017.00035","volume":"8","author":"MF Contarino","year":"2017","unstructured":"Contarino MF, Van Den Dool J, Balash Y et al (2017) Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol 8:35","journal-title":"Front Neurol"},{"key":"11395_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"11395_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","volume":"29","author":"M Fabbri","year":"2016","unstructured":"Fabbri M, Leodori G, Fernandes RM et al (2016) Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res 29:105\u2013117","journal-title":"Neurotox Res"},{"key":"11395_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213\u2013218","journal-title":"Clin Neuropharmacol"},{"key":"11395_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00415-019-09681-7","volume":"267","author":"H Hefter","year":"2020","unstructured":"Hefter H, Brauns R, \u00dcrer B, Rosenthal D, Albrecht P (2020) Effective long-term treatment with incobotulinumtoxin (Xeomin\u00ae) without neutralizing antibody induction: a monocentric, cross-sectional study. J Neurol 267:1340\u20131347","journal-title":"J Neurol"},{"key":"11395_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000646","volume":"2","author":"H Hefter","year":"2012","unstructured":"Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H (2012) Prospective analysis of neutralizing antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins\u2013a single cohort 4-year follow-up study. BMJ Open 2:e000646","journal-title":"BMJ Open"},{"key":"11395_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","volume":"121","author":"H Hefter","year":"2014","unstructured":"Hefter H, Spiess C, Rosenthal D (2014) Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm (Vienna) 121:513\u2013519","journal-title":"J Neural Transm (Vienna)"},{"key":"11395_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11235-3","author":"H Hefter","year":"2022","unstructured":"Hefter H, \u00dcrer B, Brauns R, Rosenthal D, Meuth SG, Lee JI, Albrecht P, Samadzadeh S (2022) The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-11235-3","journal-title":"J Neurol"},{"issue":"8","key":"11395_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/toxins12080499","volume":"12","author":"S Samadzadeh","year":"2020","unstructured":"Samadzadeh S, \u00dcrer B, Brauns R et al (2020) Clinical implications of difference in antigenicity of different botulinum neurotoxin type A preparations: clinical take-home messages from our research pool and literature. Toxins 12(8):499. https:\/\/doi.org\/10.3390\/toxins12080499","journal-title":"Toxins"},{"issue":"2","key":"11395_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2014.09.034","volume":"21","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21(2):111\u2013115. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.034","journal-title":"Parkinsonism Relat Disord"},{"key":"11395_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","volume":"88","author":"J Wissel","year":"2017","unstructured":"Wissel J, Bensmail D, Ferreira JJ et al (2017) Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology 88:1321\u20131328","journal-title":"Neurology"},{"key":"11395_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419\u2013423","journal-title":"J Med Econ"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11395-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:09:28Z","timestamp":1675055368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11395-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["11395"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11395-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed according to the guidelines of good clinical practice (GCP) and according to the Declaration of Helsinki. It has been approved by the local ethics committee of the University of Duesseldorf (number: 4085).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}